Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Howard University College of Medicine, Washington, DC.
Otol Neurotol. 2024 Oct 1;45(9):1078-1086. doi: 10.1097/MAO.0000000000004308. Epub 2024 Aug 21.
To test the hypothesis that conductive hearing loss (CHL) is associated with dementia, and that middle ear reconstruction (MER) associates with improved outcomes for these measures in a multinational electronic health records database.
Retrospective cohort study with propensity-score matching (PSM).
TriNetX is a research database representing about 110 million patients from the United States, Taiwan, Brazil, and India.
Subjects older than 50 years with no HL and any CHL (ICD-10: H90.0-2). Subjects of any age with and without any MER (CPT: 1010174).
Odds ratios (ORs) and hazard ratios with 95% confidence intervals (95% CIs) for incident dementia (ICD-10: F01, F03, G30).
Of 103,609 patients older than 50 years experiencing any CHL, 2.74% developed dementia compared with 1.22% of 38,216,019 patients with no HL (OR, 95% CI: 2.29, 2.20-2.37). Of patients experiencing CHL, there were 39,850 who received MER. The average age was 31.3 years, with 51% female patients. A total of 343,876 control patients with CHL were identified; 39,900 patients remained in each cohort after 1:1 PSM for HL- and dementia-related risk factors. Matched risk for developing dementia among MER recipients was 0.33% compared with 0.58% in controls (OR: 0.58, 0.46-0.72).
CHL increases the odds for dementia, and MER improves the odds for incident dementia. This study represents the first population study on the topic of CHL, MER, and dementia.
检验假设,即传导性听力损失(CHL)与痴呆有关,中耳重建(MER)与这些措施的改善结果相关,该假设基于多国电子健康记录数据库。
回顾性队列研究,采用倾向评分匹配(PSM)。
TriNetX 是一个研究数据库,代表来自美国、中国台湾、巴西和印度的约 1.1 亿患者。
年龄大于 50 岁、无听力损失(HL)和任何 CHL(ICD-10:H90.0-2)的患者。任何年龄、有或无任何 MER(CPT:1010174)的患者。
事件性痴呆(ICD-10:F01、F03、G30)的发生率比值比(OR)和 95%置信区间(95%CI)。
在 103609 名年龄大于 50 岁、经历任何 CHL 的患者中,2.74%发展为痴呆,而在 38216019 名无 HL 的患者中,1.22%发展为痴呆(OR,95%CI:2.29,2.20-2.27)。在经历 CHL 的患者中,有 39850 名患者接受了 MER。平均年龄为 31.3 岁,女性患者占 51%。确定了 343876 名患有 CHL 的对照患者;在对 HL 和痴呆相关风险因素进行 1:1 PSM 后,每个队列中仍有 39900 名患者。在接受 MER 的患者中,发生痴呆的风险比为 0.33%,而在对照组中为 0.58%(OR:0.58,0.46-0.72)。
CHL 增加了痴呆的几率,MER 改善了痴呆的发病几率。本研究代表了关于 CHL、MER 和痴呆的首个人群研究。